HMGB1 signals danger in acute coronary syndrome: Emergence of a new risk marker for cardiovascular death?

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 317-318

  Peter, Karlheinz ^a   Bobik, Alex ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Acute coronary syndrome; Amphoterin; Atherosclerosis; Biomarker; Cardiovascular death; HMGB1; Inflammation; Myocardial infarction; Necrosis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MYOCARDIAL INFARCTION;

EID: 84858699426     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.039     Document Type: Note

References (17)

1. Raucci A., Palumbo R., Bianchi M.E. HMGB1: a signal of necrosis. Autoimmunity 2007, 40:285-289.
2. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
3. den Dekker W.K., Cheng C., Pasterkamp G., Duckers H.J. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010, 209:314-320.
4. Klune J.R., Dhpar R., Cardinal J., Billiar T.R., Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008, 14:476-484.
5. Yang D., Tewary P., de la Rosa G., Wei F., Oppenheim J.J. The alarmin functions of high-mobility group proteins. Biochim Biophys Acta 2010, 1799:157-163.
6. Hashimoto T., Ishii J., Kitagawa F., et al. Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2012, 221:490-495.
7. Sørensen M.V., Pedersen S., Møgelvang R., Skov-Jensen J., Flyvbjerg A. Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2011, 4:281-286.
8. Andrassy M., Volz H.C., Igwe J.C., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
9. Takahashi M. High-mobility group box-1 (HMGB1) in ischaemic heart disease: beneficial or deleterious?. Cardiovasc Res 2008, 80:5-6.
10. Andrassy M., Volz H.C., Riedle N., et al. HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 2011, 270:245-253.
11. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011, 29:139-162.
12. Yang Q.W., Wang J.Z., Li J.C., et al. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2010, 30:243-254.
13. Albayrak Y., Albayrak A., Celik M., et al. High mobility group box protein-1 (HMGB-1) as a new diagnostic marker in patients with acute appendicitis. Scand J Trauma Resusc Emerg Med 2011, 19:27.
14. de Grauw J.C., Heinola T., van Weeren R., Kiviranta I., Konttinen Y.T. Rapid release of high mobility group box protein-1 (HMGB-1) in transient arthritis. Clin Exp Rheumatol 2010, 28:292-293.
15. Kalinina N., Agrotis A., Antropova Y., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
16. Yan X.X., Lu L., Peng W.H., et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009, 205:544-548.
17. Kanellakis P., Agrotis A., Kyaw T.S., et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31:313-319.